SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients
Frölke, Sophie C ; Geers, Daryl ; Amirkhan, Kenney G ; Pathmarajah, Danisha Sri ; van der Bom-Baylon, Nelly ; Idu, Mirza M ; van Gils, Marit ; Claireaux, Mathieu ; Geerlings, Suzanne E ; Rispens, Theo ... show 5 more
Frölke, Sophie C
Geers, Daryl
Amirkhan, Kenney G
Pathmarajah, Danisha Sri
van der Bom-Baylon, Nelly
Idu, Mirza M
van Gils, Marit
Claireaux, Mathieu
Geerlings, Suzanne E
Rispens, Theo
Series / Report no.
Open Access
Type
Journal Article
Article
Article
Language
en
Date of publication
2025-12-22
Year of publication
Research Projects
Organizational Units
Journal Issue
Title
SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients
Translated Title
Published in
Abstract
The degree to which COVID-19 vaccination induces B-cell responses in non-draining lymph nodes (LNs) is unknown. Therefore, non-draining iliac LNs and paired peripheral blood (PB) of end-stage renal disease patients were retrieved during kidney transplantation. Prior, participants received two ( = 5), three ( = 4), or four mRNA-based vaccinations ( = 3) and 4 patients had previous SARS-CoV-2 infection, of whom 2 received two vaccinations. Samples were obtained on average 79 days post-vaccination and 162 days post-infection. Spike S1(S)-binding B-cells were detected in LNs and PB 210 and 243 days after vaccination and infection, respectively. These B-cells predominantly consisted of IgG-secreting plasmablasts. In serum, a decreased IgG1/IgG4 ratio upon repeated vaccination, coherent with high fractions of S-binding IgG4 in LNs, correlated with reduced Fc-mediated functionalities but not neutralization capacity. Thus, mRNA-based COVID-19 vaccination could induce a systemic and long-lived, highly functional virus-specific B-cell response. Understanding IgG4 skewing is important for future vaccination strategies, especially in immunocompromised populations.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-025-27815-y.
